INTRODUCTION {#s1}
============

Gastric cancer, as one of the most dangerous diseases, has claimed countless lives in our accelerated society \[[@R1]\]. Although numerous markers implicated in gastric cancer have been identified, the prognosis remains to be dismal mainly due to marked heterogeneity in histologic characteristics and biological features \[[@R2]\]. In addition, patients at the same condition, such as histological grade, lymph node status and TNM staging, may have dissimilar clinical outcomes \[[@R3]\]. As a result, it is urgent to develop new reliable prognostic markers for patients with gastric cancer.

Akt, or protein kinase B, one of key proteins in the Akt/PI3K/PTEN signaling pathway, is a Serine/Threonine protein kinase that, once activated by phosphorylation, plays an important role in the process of malignant transformation \[[@R4]\]. Phosphorylated Akt (p-Akt) was implicated in inducing signals to interfere with the cell apoptosis, and promoting abilities of proliferation and motility through a crucial mechanism, the activation of mTOR (mammalian target of rapamycin) \[[@R4], [@R5], [@R6]\]. Overexpressed p-Akt was considered as an indicator of poor prognosis in many malignancies. For example, a recent meta-analysis reported that high p-Akt expression was significantly associated with worse overall survival in patients with breast cancer (HR=1.52, 95%CI:1.29--1.78, P=0.001) \[[@R7]\]. This prognostic value were also showed in another two meta-analyses which summarized a same conclusion that elevated p-Akt expression was related to poor survival in patients with non-small cell lung cancer \[[@R8], [@R9]\].

In gastric cancer, many trials also showed a negative relationship between p-Akt expression and survival. However, some studies failed to detect a significant relationship, and some even obtained a positive one. In particular, several trials gained contradictory results through univariate and multivariate analyses. Furthermore, there were no systematic reviews with meta-analysis about the prognostic value of p-Akt in gastric cancer.

In light of the outstanding controversy of p-Akt, we launched a systematic review of available studies with meta-analysis to evaluate the prognostic value of p-Akt in patients with gastric cancer.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

As shown in Figure [1](#F1){ref-type="fig"}, a total of 2727 articles were retrieved in the initial search. In addition, 31 records were yielded by manual searching. After removing 264 duplicated studies, we read the titles and abstracts of the 2494 studies left, and then, excluded 2356 citations, leaving 138 studies for further full-text review. After punctiliously reading, 125 studies were excluded: 121 studies, including reviews or letters, were excluded for no or insufficient survival data; and four studies \[[@R10]--[@R13]\] were removed because they only investigated Akt expression, but not p-Akt. Therefore, 13 eligible studies \[[@R14]--[@R26]\] with 2261 patients in total, were enrolled finally in this meta analysis.

![Flow chart for the selection of records to include](oncotarget-08-59878-g001){#F1}

Study characteristics {#s2_2}
---------------------

The basic characteristics and results of the 13 eligible studies were summarized in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. Briefly, 11 studies were conducted in Asian populations, while the remaining used Caucasian populations \[[@R16], [@R20]\]; study sample sizes ranged from 28 to 424; all of the cohorts were treated with surgery, except one treated only with chemotherapy \[[@R20]\], and the treatment of another two studies was a combined regimen of surgery plus chemotherapy \[[@R17], [@R21]\]; p-Akt expression was detected in the cytoplasm or nucleus of the tissues in all the studies, with rabbit or mouse antibodies, and polyclonal or monoclonal antibodies, but two studies \[[@R23], [@R24]\] didn\'t reported what kind of p-Akt they used; the cut-offs were identified by the extent or intensity, but the cut-off values of p-Akt varied in each study. Seven of them selected a moderate value, such as 50%, score 3/6 and the median level, and five chose "\>10%" according to the extent of the staining. However, the left one, "Murakami 2007", considered the staining \>1% as a positive value. Among all of them, five reported that high level of p-Akt expression was related to poor survival; and six revealed no significant impact on survival. However, two reported p-Akt as an indicator of good prognosis. Ten of these thirteen cohorts reported the relationship between p-Akt expression and overall survival. Among them, four gave a HR directly from univariate analysis, and another six only presented Kaplan--Meier survival curves with or without multivariate HRs. So, we estimated HRs from these six K-M curves.

###### Characteristics of included studies

  First author   Year   Region   Sample   Measure method   Age (years)   N. of M/F   Primary antibody   Treatment      Follow-up
  -------------- ------ -------- -------- ---------------- ------------- ----------- ------------------ -------------- -------------------
  Bian           2015   China    Tissue   IHC              NR            NR          Rabbit Ab          Surgery        Median 49 months
                                                                                                                       (2-80months)
  Chang          2015   Korea    Tissue   IHC              Mean 58.1     285/139     Rabbit pAb         Surgery        Mean 82.3 months;
                                                           Median 61                                                   Median96.1months
                                                                                                                       (1 --131 months)
  Cinti          2008   Italy    Tissue   IHC              34-83years    16/34       mAb                Surgery        at least 5 years
  Han            2011   China    Tissue   IHC              Median 53     85/23       Rabbit pAb         Surgery        About 5 years
                                                                                                        Chemotherapy   
  Kobayashia     2006   Japan    Tissue   IHC              NR            NR          Rabbit pAb         Surgery        \>40 months
  Liang          2015   China    Tissue   IHC              NR            NR          mAb                Surgery        \>5 years
  Luber          2011   Europe   Tissue   IHC              Median 63     30/9        Mouse mAb          Chemotherapy   Median 379 days
  Murakami       2007   Japan    Tissue   IHC              Mean 70.8     84/56       Mouse pAb          Surgery        at least 5 years
                                                                                                        Chemotherapy   
  Murayama       2009   Japan    Tissue   IHC              Median 65     77/32       Rabbit pAb         Surgery        Median 1953 days
                                                                                                                       (50-- 3197 days)
  Nam            2003   Korea    Tissue   IHC              Mean 54.8     210/101     NR                 Surgery        Mean 54 months
                                                                                                                       (1-72 months)
  Sasaki         2014   Japan    Tissue   Immunoblot       NR            NR          NR                 Surgery        \>5 years
  Sukawa         2012   Japan    Tissue   IHC              Median 71     157/74      pAb                Surgery        About 10 years
  Xue            2012   China    Tissue   IHC              Median65.5    158/71      Mouse pAb          Surgery        \>5 years

N. of P.: the number of patients; M/F: male/female; mAb: monoclonal antibody; pAb: polyclonal antibody; NR: not reported.

###### Characteristics of included studies

  First author   Year   N. of P.   Location   Scoring method   Cut-off of p-Akt high expression       Outcome   Obtainment   HR      95%CI
  -------------- ------ ---------- ---------- ---------------- -------------------------------------- --------- ------------ ------- --------------
  Bian           2015   396        C          EI               Score 3-6                              OS        U            1.931   1.379-2.703
                                                                                                      OS        M            1.332   0.943-1.882
                                                                                                      RFS       U            1.537   1.074-2.199
                                                                                                      RFS       M            1.221   0.847-1.762
  Chang          2015   424        C          EI               \>50%or moderate to strong intensity   DSS       M            0.724   0.485-1.083
  Cinti          2008   50         C          E                \>10%                                  RFS       K-M          3.04    1.18-7.85
  Han            2011   108        CN         EI               Score \>6                              DFS       K-M          1.67    0.86-3.24
  Kobayashia     2006   88         C          E                \>50%                                  OS        K-M          2.16    0.86-5.43
  Liang          2015   107        C          EI               Score \>1.5                            OS        K-M          1.78    1.09-2.91
                                                                                                      DFS       K-M          1.76    1.02-3.04
  Luber          2011   28         N          E                \>10%                                  OS        U            1.1     0.2-4.8
                                                                                                      TTP       U            0.5     0.1-1.5
  Murakami       2007   140        CN         E                \>1%                                   OS        M            0.227   0.119--0.433
                                                                                                      OS        K-M          1.63    0.64-4.10
  Murayama       2009   109        C          EI               \>10% or strongly stained              OS        M            0.35    0.11-1.16
                                                                                                      OS        K-M          0.16    0.04-0.64
                                   N                                                                  OS        M            1.787   0.80-3.99
                                   CN                                                                 OS        K-M          1.36    0.34-5.48
  Nam            2003   311        C          E                Moderate to strong                     OS        K-M          0.46    0.23-0.92
  Sasaki         2014   40         CN         E                Median of the protein level            OS        U            2.453   0.945-6.368
                                                                                                      OS        M            0.572   0.236-1.389
  Sukawa         2012   231        CN         E                \>10%                                  OS        U            1.75    1.12-2.80
  Xue            2012   229        CN         E                \>10%                                  OS        K-M          1.73    1.16-2.59

N. of P.: the number of patients; C: cytoplasm; N: nucleus; CN: cytoplasm and nucleus; OS: overall survival; DFS: disease-free survival; DSS: disease-specific survival; TTP: time to progression; RFS: recurrence-free survival; HR: hazard ratio; "M": the multivariate analysis; "U": the univariate analysis; "K-M": Kaplan--Meier survival curves; "E": identifying the cut-off by the extent; "I": identifying the cut-off by the intensity; "EI": both by the extent and the intensity.

Quality assessment {#s2_3}
------------------

The study quality scores based on the NOS, ranged from 6 to 8, with a mean of 6.85. None of these thirteen studies obtained a NOS≤5, indicating that all of them had high levels of methodological quality in our meta-analysis (Table [3](#T3){ref-type="table"}).

###### Quality assessment of eligible studies with Newcastle-Ottawa Scale

  First author   Year   NOS   Selection   Comparability   Outcome
  -------------- ------ ----- ----------- --------------- ---------
  Bian           2015   6     ★★★\*       ★               ★★\*
  Chang          2015   8     ★★★         ★★              ★★★
  Cinti          2008   7     ★★★         ★★              ★★
  Han            2011   7     ★★★\*       ★\*             ★★★
  Kobayashia     2006   6     ★★★         ★               ★★\*
  Liang          2015   6     ★★\*        ★★\*            ★★\*
  Luber          2011   7     ★★★         ★               ★★★\*
  Murakami       2007   8     ★★★         ★★              ★★★\*
  Murayama       2009   8     ★★★         ★★\*            ★★★
  Nam            2003   6     ★★★\*       ★★              ★\*
  Sasaki         2014   7     ★★          ★★              ★★★\*
  Sukawa         2012   7     ★★★\*       ★               ★★★\*
  Xue            2012   6     ★★★         ★\*             ★★

\*The score was produced by discussion.

p-Akt expression and survival outcome {#s2_4}
-------------------------------------

16 results, obtained from ten trials with OS, were divided into three groups, univariate, multivariate and estimate, by which three pooling HRs were produced (HR=1.88, 95%CI:1.45-2.43, P\<0.00001; HR=0.66, 95%CI: 0.29-1.52, P=0.33; and HR=1.13, 95%CI: 0.65-1.95, P=0.67, respectively. Figure [2](#F2){ref-type="fig"}). However, only the group, univariate, with a I^2^=0%, had no heterogeneity. Then, we combined the two groups, univariate and estimate, and figured out a new incorporative HR being 1.41 (95%CI: 1.01-1.97, P=0.04, Figure [2D](#F2){ref-type="fig"}). Though with highly significant heterogeneity (I^2^=62%, Ph=0.004), this new result also had significance in statistics, illustrating that high p-Akt expression was significantly associated with poor OS of patients with gastric cancer.

![Forest plot of hazard ratios (HRs) for OS of high p-Akt expression versus low expression in gastric cancer\
**(A)** The HRs for OS in univariate analysis; **(B)** the HRs for OS in multivariate analysis; **(C)** the HRs for OS in estimate; **(D)** the HRs for OS in univariate analysis and estimate.](oncotarget-08-59878-g002){#F2}

We also calculated the pooled HRs of DFS and RFS, and obtained statistically significant estimates (HR=1.72, 95%CI: 1.13-2.63, P=0.01; and HR=1.67, 95%CI: 1.20-2.34, P=0.003, respectively), showing elevated p-Akt expression associated with poor prognosis. However, we failed to obtain more pooling HRs of other survival outcomes.

Subgroup analyses {#s2_5}
-----------------

Due to the heterogeneity, we performed the subgroup analyses, presented in Table [4](#T4){ref-type="table"}, by stratifying the combined data according to location (C vs. N vs. CN), main treatment (surgical vs. non-surgical), study region (Asian vs. Caucasian), sample size (\<100 vs. ≧100), obtainment (univariate vs. estimate), scoring method (E vs. EI), cut-off (1% vs. 10% vs. Moderate), measure method (IHC vs. Immunoblot) and primary antibody (Rabbit vs. Mouse vs. pAb vs. mAb vs. NR). Because of too few cohorts in multivariate analysis, and no heterogeneity in univariate analysis, we conducted the subgroup analyses only in the combination of univariate analysis and estimate, called "U+E", and we failed to get any potential source of heterogeneity in "U+E".

###### Subgroup analyses of the association between high p-Akt expression and overall survival in the group "U+E" of patients with gastric cancer

  Subgroup           Data sets   Model    HR (95%CI)            P           I^2^   Ph
  ------------------ ----------- -------- --------------------- ----------- ------ ----------
  All                11          Random   1.41 \[1.01, 1.97\]   0.04        62%    0.004
  Location                                                                         
  C                  5           Random   1.04 \[0.51, 2.10\]   0.92        84%    \<0.0001
  N                  1           \-       1.10 \[0.20, 6.05\]   0.91        \-     \-
  CN                 5           Fixed    1.76 \[1.35, 2.30\]   \<0.0001    0%     0.96
  Region                                                                           
  Asian              10          Random   1.42 \[1.00, 2.01\]   0.05        65%    0.002
  Caucasian          1           \-       1.10 \[0.20, 6.05\]   0.91        \-     \-
  Treatment                                                                        
  Surgical           10          Random   1.42 \[1.00, 2.01\]   0.05        65%    0.002
  Non-surgical       1           \-       1.10 \[0.20, 6.05\]   0.91        \-     \-
  Sample size                                                                      
  \<100              3           Fixed    2.09 \[1.12, 3.87\]   0.02        0%     0.72
  ≧100               8           Random   1.28 \[0.86, 1.91\]   0.22        72%    0.0009
  Obtainment                                                                       
  univariate         4           Fixed    1.88 \[1.45, 2.43\]   \<0.00001   0%     0.85
  estimate           7           Random   1.13 \[0.65, 1.95\]   0.67        73%    0.001
  Scoring method                                                                   
  E                  7           Random   1.46 \[0.96, 2.21\]   0.08        57%    0.03
  EI                 4           Random   1.21 \[0.60, 2.44\]   0.59        75%    0.008
  Cut-off                                                                          
  1%                 1           \-       1.63 \[0.64, 4.15\]   0.31        \-     \-
  10%                5           Random   1.19 \[0.65, 2.18\]   0.57        64%    0.03
  Moderate           5           Random   1.51 \[0.89, 2.56\]   0.13        73%    0.005
  Measure method                                                                   
  IHC                10          Random   1.35 \[0.95, 1.92\]   0.10        64%    0.003
  Immunoblot         1           \-       2.45 \[0.94, 6.37\]   0.07        \-     \-
  Primary antibody                                                                 
  Rabbit             4           Random   1.13 \[0.45, 2.85\]   0.79        75%    0.007
  Mouse              3           Fixed    1.68 \[1.17, 2.41\]   0.005       0      0.88
  pAb                1           \-       1.75 \[1.12, 2.73\]   0.02        \-     \-
  mAb                1           \-       1.78 \[1.09, 2.91\]   0.02        \-     \-
  NR                 2           Random   1.03 \[0.20, 5.29\]   0.97        87%    0.005

C: cytoplasm; N: nucleus; CN: cytoplasm and nucleus; U+E: univariate analysis + estimate of Kaplan--Meier survival curves.

p-Akt expression and clinicopathological features {#s2_6}
-------------------------------------------------

In our study, we also assessed the relationship of p-Akt expression with pathological differentiation, N status and tumor staging. In spite of no significant difference between p-Akt expression and pathological differentiation, we found that high p-Akt expression was associated with lymph node metastasis and advanced gastric cancer (for pathological differentiation, HR=1.17, 95%CI: 0.94-1.46, P=0.15; for N status, HR=1.34, 95%CI: 1.11-1.62, P=0.003; and for tumor staging, HR=1.60, 95%CI: 1.27-2.02, P\<0.0001).

Sensitivity analyses {#s2_7}
--------------------

By using sensitivity analysis, we deleted an individual result at a time and pooled the others into a new HR to compare with the previous one, and all studies of this meta-analysis were assessed to value the stability of our results. Pooled results for "univariate", "multivariate" and "estimate" were insensitive to the removal of individual studies, and the corresponding combined HRs were not substantially changed (data not shown, Figure [3](#F3){ref-type="fig"}).

![Influence analysis\
**(A)** was about univariate analysis; **(B)** was about multivariate analysis; **(C)** was about estimate.](oncotarget-08-59878-g003){#F3}

Publication bias {#s2_8}
----------------

We conducted the publication bias assessment of the thirteen studies by funnel plots and Egger\'s test. No obvious asymmetry was found in all of the three groups (Figure [4](#F4){ref-type="fig"}), and results of Egger\'s test also suggested no evidence of publication bias in "univariate", "multivariate" and "estimate" (P=0.752, P=0.367 and P=0.278, respectively).

![Funnel plot of 10 studies\
**(A)** was about univariate analysis; **(B)** was about multivariate analysis; **(C)** was about estimate.](oncotarget-08-59878-g004){#F4}

DISCUSSION {#s3}
==========

p-Akt, as a potential biomarker of poor prognosis in various malignant tumors, has aroused prominent interest in this critical period of high morbidity and mortality of neoplasms. Although some studies failed to find any significance of the relationship between p-Akt expression and survival, all of these three meta-analyses proved that over-expression of p-Akt was correlated with an unfavorable outcome in carcinomas \[[@R7], [@R8], [@R9]\]. In spite of small sample sizes and controversial reports, many studies have investigated the prognostic value of p-Akt in gastric cancer. Furthermore, no meta-analyses have previously been conducted on the prognostic value of p-Akt in gastric cancer. Hence, we performed this meta-analysis to clarify this question and explore its prognostic value in gastric cancer.

To the best of our knowledge, the present meta-analysis, including a total of 13 studies with 2261 patients, was the first meta-analysis systematically evaluating the prognostic value of p-Akt in patients with gastric cancer, and showed that over-expressed p-Akt was a strong predictor of inferior overall survival in the univariate analysis in patients with gastric cancer. Though without any significance in multivariate analysis and estimated K-M curves, a poor prognosis associated with high p-Akt expression could be found in the group, "U+E", which we pooled results obtained from studies in the group of univariate analysis, and those in the group of estimate. Because those estimates calculated form curves was univariate, but not multivariate, we also figured out estimates from K-M curves of studies only with multivariate analysis \[[@R8]\]. In our following sensitivity analysis, no substantial changes were found, and another strength of this meta-analysis was that no publication biases were detected, indicating that our combined results may be unbiased. In our study, we also found that high p-Akt expression was correlated with lymph node metastasis and advanced gastric cancer.

Many molecular mechanisms, associated with the alteration of p-Akt expression in malignancies, have been explored out. In a total of 202 gastric cancer patients, Hisamatsu demonstrated that there was a positive relationship between p-Akt and EGFR, both of which were significantly correlated with DNA aneuploidy \[[@R27]\]. The signaling pathway, Akt/PI3K/PTEN/mTOR, was related to the pathogenic process of several neoplastic diseases \[[@R28], [@R29]\], and the activation of this signaling pathway was also associated with poor survival in solid tumors \[[@R30]\]. Many molecular biomarkers, such as SPARC, ZIC1 and NM23-H1, were up-regulated or down-regulated through the Akt/PI3K/PTEN/mTOR signaling pathway, and promoted or inhibited the growth of human tumors \[[@R31]--[@R33]\]. Besides, overexpression of these proteins might also be linked to better or worse survival \[[@R34]--[@R36]\]. Moreover, some drugs, such as 5-FU and LY294002, could downregulate the activated p-Akt to overcome intrinsic and acquired resistance of 5-FU in SNU-719 cells, a EBV gastric cancer cell line \[[@R37]\]. Therefore, this pro-oncogenic signal, p-Akt, the prognostic value of which will be more important, especially with respect to Akt/PI3K/PTEN/mTOR signaling pathway, has become a promising target for the development of drugs.

Admittedly, several limitations were unavoidable in our meta-analysis. Firstly, though with 2261 patients in total, the sample size was still small. The studied patients couldn\'t reflect the real outcome of whole gastric cancer population and this could cause some selection bias or else. Secondly, despite the HRs estimated from Kaplan-Meier curves were results of univariate analysis, these estimates were inaccurate and might influence our results in the groups, estimate and "U+E". In addition, although many meta-analyses combined HRs whether with univariate analysis or with multivariate analysis, our study considered that HRs with univariate analysis, including estimated from univariate curves, included some confounding factors, but HRs with multivariate analysis precluded these factors, to some degree. Although HRs with multivariate analysis seemed to be better, the capability to eliminate factors of each study must be different. Thus, all groups should be calculated and discussed in our manuscript. Thirdly, Meta-analysis is an effective method to combine the results of RCT, but recently, this approach has been applied successfully for evaluation of prognostic indicators in patients with malignant diseases. However, these studies investigating genes expression couldn\'t be designed as RCT, so all studies were non-RCT. Fourthly, although we obtained a significant pooled HR without any heterogeneity when deleting two studies, "Nam 2003" and "Murayama 2009 C", in the sensitivity analysis, we failed to find the potential source of heterogeneity in the subgroup analyses, which meant that various factors might be lumped together. So, some possible sources of heterogeneity might be undetected. Fifthly, in our subgroup analyses, Akt expression seemed to correlate with prognostic outcome only in studies conducted in Asian countries or surgical treatment (only one study conducted in Caucasian and non-surgical treatment). Besides, the cut-offs were various and we divided them into three parts, "\>1%", "\>10%" and "moderate", but we failed to gain any significant HR, and the heterogeneity was still existent. Thus, the pooling HR combined by results with univariate analysis and results estimated by K-M curves might be unstable, and more researches, with a standard cut-off, on p-Akt expression in gastric cancer should be conducted. In addition, some unpublished studies and negative studies could also be ignored. Because we launch this rigorous search to collect as many studies as possible, and then funnel plots and Egger\'s test both showed no obvious publication bias in our results, the influence of these studies might be limited. Last but not least, we only searched the studies in English and Chinese. This could lose some available studies in other languages.

In conclusion, the elevated p-Akt expression might be associated with a poor prognosis in patients with gastric cancer. This meta-analysis showed the current status of many inconsistencies and imperfections in researches of p-Akt in gastric cancer. Thus, more rigorous studies should be performed to confirm our conclusion and explore its molecular functions.

MATERIALS AND METHODS {#s4}
=====================

Publication selection {#s4_1}
---------------------

We searched Pubmed, EMBASE, Cochrane Library, CNKI (China National Knowledge Infrastructure), Wanfang (Chinese database) and CBM (China Biological Medicine Database) from their incipiency to January, 2016. The key words were used as follow: "Akt", "phospho-Akt", "protein kinase B", "PKB", "gastric", "stomach", "prognosis" and "survival". Reference lists of reviews and articles were hand-searched for potential articles. Also, manuscripts were manually scrutinized to obtain additional trials most relevant to this review. Only studies published in peer reviewed journals in English or Chinese were included. All the initially identified articles were scanned independently by two reviewers (Fang Cao and Cong Zhang). However, we had no protocol developed for this review.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Inclusion criteria were: (a) clinical trials reported patients with gastric cancer; (b) p-Akt protein expression in the tissue specimens of patients with gastric cancer, was measured with immunohistochemistry (IHC) or immunoblot analysis; (c) studies reported the association between p-Akt expression and survival outcome; (d) studies contained HRs and 95% CI for OS or other outcomes which either were reported or could be estimated from K-M curves; (e) if the study population was overlapping or duplicated, only the most recent or the most complete report would be enrolled.

Exclusion criteria were: (a) experiment only *in vitro* or *in vivo* but not based on patients; (b) literature published as abstracts, letters, reviews, editorials, case reports and expert opinions; (c) studies without HRs and its corresponding 95%CI about OS, or K-M survival curves; (d) studies only with data about mutations of the Akt gene or only reporting mRNA; (e) similar and repeated studies.

Disagreement was resolved by discussion between two reviewers (Fang Cao and Cong Zhang) or consultation with a third one (Wei Han).

Data extraction and quality assessment {#s4_3}
--------------------------------------

We extract the following information from each study: (a) general information, including first author, publication year, region of origin, sample size, gender and age of patients, and the follow-up duration; (b) clinical outcomes, including OS or others, with HRs and 95%CI. If no univariate or unadjusted HR was available, we used a digitizing program, Engauge Digitizer, which could rendered K-M curves into numbers. And then, we put the data into a Tierney table, by which the estimated HR with its corresponding 95%CI were figured out immediately \[[@R38]\]. This estimate was performed independently by two reviewers (Fang Cao and Cong Zhang), and the disagreement was also resolved by discussion between the two reviewers or consultation with a third reviewer (Wei Han). Note that, despite we obtained univariate unadjusted HRs, multivariate adjusted HRs and estimated HRs, we only combined univariate unadjusted HRs and estimated HRs into a new pooled estimate, rather than the multivariate adjusted HRs \[[@R8]\].

Two independent reviewers (Fang Cao and Cong Zhang) assessed the quality of each study with the Newcastle-Ottawa Quality Assessment Scale (NOS) \[[@R39]\]. This scale, including three parts, selection, comparability and outcome, mainly used in non-RCT studies. We used the quality assessment scale of cohort studies. A study with NOS ≥ 6 was regarded as a high-quality study \[[@R40]\]. Disparity was also resolved by discussion or consultation.

Data synthesis and analysis {#s4_4}
---------------------------

OS (overall survival), associated with p-Akt expression in patients with gastric cancer, was the primary outcome. Other survival outcomes, including DFS (disease-free survival), TSS (tumor-special survival), DSS (disease-specific survival), TTP (time to progression), MFS (metastasis-free survival) and RFS (recurrence-free survival), were also collected. HR with its 95% CI was used to be the effect measure of interest. Estimates of HRs were weighted and pooled using the Mantel-Haenszel method. A pooled HR\>1.00, with its 95%CI did not overlap 1, indicated a worse survival for the group with p-Akt expression.

The Q and I^2^ test were used to measure the heterogeneity among cohorts. A random or Fixed model was identified by the heterogeneity analysis. A fixed effect model was selected if I^2^\<50%; and the random effect model was applied if I^2^≧50%. An I^2^\>50% indicated substantial heterogeneity in studies, and we would perform subgroup analyses to detect potential sources of heterogeneity.

A funnel plot and Egger\'s linear regression test were used to assess the latent publication bias, and in Egger\'s test, a value \<0.05 indicated an inevitable significant publication bias \[[@R41]\].

All the analyses were conducted by STATA statistical software package version 12.0 (STATA12) and Review Manager software version 5.3 (The Cochrane Collaboration, RevMan5.3). All statistical tests were two-tailed and P\<0.05 was considered statistically significant.
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